SearchPublisher and Institutes
You are here: Home :: Area NEM :: Medical science :: Human medicine
Philip B. Mitchell
Therapeutic drug monitoring of non-tricyclic antidepressant drugs
Keywords: cytochrome P450, non-tricyclic antidepressant, selective serotonin reuptake inhibitors (SSRIs), therapeutic drug monitoring, venlafaxine
Therapeutic drug monitoring (TDM) of many of the tricyclic antidepressants (TCAs) has been demonstrated to be of clear clinical value. This article reviews studies of TDM for the selective serotonin reuptake inhibitors (SSRIs) and other non-tricyclic antidepressants such as venlafaxine, nefazodone, trazodone, mianserin and bupropion. No definitive therapeutic concentrations have been demonstrated for these agents, nor have levels indicative of toxicity been reported. The major benefit of TDM for these agents would appear to be in the assessment of the apparently treatment-refractory depressed patient, to determine whether such lack of response is related to inadequate levels that would suggest either poor compliance, ultra-rapid metabolism, or drug interactions leading to induction of metabolising enzymes. Potential future applications of TDM, in conjunction with genotyping of cytochrome P450 enzymes and pharmacogenomic evaluations, are discussed.
Clinical Chemical Laboratory Medicine, Walter de Gruyter
Print ISSN: 1434-6621
Volume: 42, 11/2004
Pages: 1212 - 1218